NRAS codon(s) 12, 13, 61, 146 any
Non-Small Cell Lung Carcinoma
NRAS is a member of the RAS family of oncogenes and activating mutations of NRAS have been reported in about 1% of NSCLCs and are mostly exclusive of other known driver mutations. The Q61 codon is most frequently affected. In preclinical studies, cell lines harboring NRAS mutation(s) showed variable sensitivities to pathway inhibitors.
Ohashi et al. Characteristics of lung cancers harboring NRAS mutations. Clinical Cancer Research 19.9 (2013): 2584-2591.
Vujic I et al. Mutant NRASQ61 shares signaling similarities across various cancer types – potential implications for future therapies. Oncotarget. 2014;5(17):7936-7944.
Sholl LM, Aisner DL, Varella-Garcia M, Berry LD, Dias-Santagata D, Wistuba II, Chen H, Fujimoto J, Kugler K, Franklin WA, Iafrate AJ, Ladanyi M, Kris MG, Johnson BE, Bunn PA, Minna JD, Kwiatkowski DJ; LCMC Investigators. Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. J Thorac Oncol. 2015 May;10(5):768-77. doi: 10.1097/JTO.0000000000000516. PubMed PMID: 25738220; PubMed Central PMCID: PMC4410843.
Araujo LH, Lammers PE, Matthews-Smith V, Eisenberg R, Gonzalez A, Schwartz AG, Timmers C, Shilo K, Zhao W, Natarajan TG, Zhang J, Yilmaz AS, Liu T, Coombes K, Carbone DP. Somatic Mutation Spectrum of Non-Small-Cell Lung Cancer in African Americans: A Pooled Analysis. J Thorac Oncol. 2015 Oct;10(10):1430-6. doi: 10.1097/JTO.0000000000000650. PubMed PMID: 26301800; PubMed Central PMCID: PMC4618391.
Disclaimer: You assume full responsibility for all risks associated with using this PMKB website. The IPM makes no guarantee of the comprehensiveness, reliability or accuracy of the information on this website and the IPM assumes no responsibility for errors in the information associated with this web site. Healthcare providers and patients must integrate all clinical and laboratory findings as well as information from a variety of sources before deciding on appropriate clinical care options.